Patritumab deruxtecan - Daiichi Sankyo Company
Alternative Names: HER3-DXd; MK-1022; Patritumab-DX-8951 conjugate; U3-1402; U3-1402aLatest Information Update: 03 Jul 2024
At a glance
- Originator Daiichi Sankyo Company
- Developer Daiichi Sankyo Company; Merck & Co; SCRI Development Innovations; SOLTI Breast Cancer Research Group
- Class Alkaloids; Antibodies; Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Non-small cell lung cancer
- Phase II Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
- Phase I/II HER2 positive breast cancer
Most Recent Events
- 27 Jun 2024 The US FDA has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) to inspection findings at third-party manufacturer
- 25 Apr 2024 Samsung Medical Center plans a phase II Basket trial for Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in South Korea (IV, Infusion) (NCT06383884)
- 07 Apr 2024 Pharmacodynamics data from a preclinical study in hepatoblastoma and rhabdomyosarcoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)